NeuroVax
Other names:
In development for: Relapsing/remitting MS
Status: Phase II
Last updated: April 2008
How does it work?
NeuroVax contains a combination of three protein fragments (peptides) which appear on the surface of T-cells involved in the immune response in MS. Recent studies have suggested that treatment with NeuroVax stimulates production of certain regulatory T-cells, which in turn decrease the levels of other T-cells which attack myelin.
How is it given?
NeuroVax is injected into the muscle every four weeks.
Clinical studies
A phase II clinical trial is underway in Central and Eastern Europe.
